Masashi Miyamoto, Kyowa Kirin CEO

Ky­owa Kirin pulls the plug on drug de­vel­op­ment for suc­ces­sor to Parkin­son's drug Nouri­anz

Three years af­ter Japan’s Ky­owa Kirin se­cured FDA ap­proval for an add-on ther­a­py to lev­odopa in Parkin­son’s, the com­pa­ny has scrapped its po­ten­tial suc­ces­sor.

Ky­owa Kirin is­sued a short state­ment Fri­day on the new de­vel­op­ment af­ter con­duct­ing two Phase II stud­ies in Japan: an ear­ly Phase II with 175 par­tic­i­pants fin­ished in 2017, and a Phase IIb with 502 par­tic­i­pants that con­clud­ed in 2020. The com­pa­ny said those stud­ies pro­vid­ed a sig­nal the drug could be po­ten­tial­ly ef­fec­tive in Parkin­son’s by it­self and as a com­bi­na­tion ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.